Teck Khoo, MD
Endocrinology, Diabetes & Metabolism · Des Moines, IANPI 1487624037
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $4,888 of the $6,215 with a category attached, or 78.6%. 16 manufacturers reported payments, led by Boehringer Ingelheim at 49.8% of the total. Reporting peaked in 2019 at $4,958 and has fallen 90.9% since, to $450 in 2025.
Across 40 payments — averaging $155.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$3K
- Lilly USA, LLC$2K
- Chiesi USA, Inc.$300
- Amgen$277
- Abbott$67
- Novo Nordisk$61
- plus $235 from 10 others
What the payments were for
- Consulting fees$4888%
- Speaking & faculty fees$4,88879%
- Food & beverage$81713%
- Education$230%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 8 | $3,096 |
| Lilly USA, LLC | 8 | $2,180 |
| Chiesi USA, Inc. | 1 | $300 |
| Amgen(2 entities) | 3 | $277 |
| Abbott | 4 | $67 |
| Novo Nordisk | 4 | $61 |
| Medtronic | 1 | $44 |
| Antares Pharma, Inc. | 2 | $38 |
| Tandem Diabetes Care, Inc. | 2 | $30 |
| Nevro Corp. | 1 | $26 |
| Insulet Corporation | 1 | $22 |
| AbbVie | 1 | $19 |
| Johnson & Johnson | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Senseonics, Incorporated | 1 | $13 |
| Shire North American Group Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,215 in reported general payments places this provider in the 85th percentile of 38 endocrinology, diabetes & metabolism providers in Iowa.
See all endocrinology, diabetes & metabolism providers in Iowa →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 233 | $296,892 |
| JardianceEmpagliflozin | 185 | $198,479 |
| Tresiba Flextouch U-200Insulin Degludec | 74 | $177,262 |
| TrulicityDulaglutide | 112 | $142,788 |
| MounjaroTirzepatide | 109 | $124,130 |
| Humalog Kwikpen U-200Insulin Lispro | 29 | $100,310 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 41 | $88,765 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 123 | $77,735 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 68 | $66,867 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 43 | $55,205 |
| Tresiba Flextouch U-100Insulin Degludec | 77 | $52,971 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 198 | $36,570 |
| Humalog Kwikpen U-100Insulin Lispro | 105 | $34,999 |
| Novolog FlexpenInsulin Aspart | 90 | $26,149 |
| JanuviaSitagliptin Phosphate | 27 | $18,933 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $61 | $327,579285 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $2,180 | $276,585249 claims |
| Boehringer IngelheimJardiance | $3,096 | $198,479185 claims |
| AbbVieSynthroid | $19 | $3,82775 claims |
| Sanofi-aventis U.S. LLCLantus | $15 | $3,24120 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 38 endocrinology, diabetes & metabolism providers in Iowa.
Other endocrinology, diabetes & metabolism in Des Moines
- Anuj BhargavaDes Moines$30K
- Vanitha SingaramDes Moines$824
- Pierre TheumaDes Moines$681
- Gurbir GillDes Moines$480
- Pearl DyDes Moines$430
- Daniela MilaniDes Moines$296
- Mary FigaroDavenport$73K
- Ayotunde DokunIowa City$31K
- Marcelo CorreiaIowa City$10K
- Thomas OdorisioIowa City$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.